Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Update

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the target of a significant decline in short interest in February. As of February 15th, there was short interest totalling 149,800 shares, a decline of 35.5% from the January 31st total of 232,100 shares. Currently, 2.1% of the company’s shares are short sold. Based on an average daily volume of 77,600 shares, the days-to-cover ratio is currently 1.9 days.

Marker Therapeutics Price Performance

NASDAQ:MRKR opened at $1.53 on Friday. Marker Therapeutics has a one year low of $1.45 and a one year high of $5.99. The firm has a 50-day moving average of $2.30 and a 200-day moving average of $3.02.

Wall Street Analyst Weigh In

Separately, Brookline Capital Management raised Marker Therapeutics to a “strong-buy” rating in a research report on Monday, February 10th.

Insiders Place Their Bets

In other news, Director Steve Elms bought 11,085 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was acquired at an average cost of $3.20 per share, with a total value of $35,472.00. Following the transaction, the director now directly owns 325,370 shares of the company’s stock, valued at approximately $1,041,184. This represents a 3.53 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Enterprise Associates 16 New purchased 554,250 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average cost of $3.20 per share, for a total transaction of $1,773,600.00. Following the completion of the purchase, the insider now owns 1,625,678 shares in the company, valued at $5,202,169.60. This trade represents a 51.73 % increase in their position. The disclosure for this purchase can be found here. 14.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Marker Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Invst LLC bought a new position in shares of Marker Therapeutics in the third quarter valued at approximately $56,000. Millennium Management LLC bought a new position in Marker Therapeutics during the 4th quarter valued at $50,000. Northern Trust Corp boosted its holdings in Marker Therapeutics by 66.9% during the 4th quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock worth $168,000 after acquiring an additional 21,703 shares during the last quarter. NEA Management Company LLC grew its stake in shares of Marker Therapeutics by 51.7% in the 4th quarter. NEA Management Company LLC now owns 1,625,678 shares of the company’s stock worth $5,056,000 after acquiring an additional 554,250 shares in the last quarter. Finally, Alyeska Investment Group L.P. purchased a new stake in shares of Marker Therapeutics in the fourth quarter valued at about $2,847,000. 22.39% of the stock is owned by institutional investors.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.